AR028505A1 - Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco - Google Patents

Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco

Info

Publication number
AR028505A1
AR028505A1 ARP010100587A ARP010100587A AR028505A1 AR 028505 A1 AR028505 A1 AR 028505A1 AR P010100587 A ARP010100587 A AR P010100587A AR P010100587 A ARP010100587 A AR P010100587A AR 028505 A1 AR028505 A1 AR 028505A1
Authority
AR
Argentina
Prior art keywords
make
antagonist
preparation
cannabinoid receptors
tobacco consumption
Prior art date
Application number
ARP010100587A
Other languages
English (en)
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR028505A1 publication Critical patent/AR028505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Utilizacion de N-piperidin-5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metilpirazol-3-carboxamida, para que sea más fácil detener el consumo de tabaco.
ARP010100587A 2000-02-09 2001-02-09 Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco AR028505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
AR028505A1 true AR028505A1 (es) 2003-05-14

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100587A AR028505A1 (es) 2000-02-09 2001-02-09 Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco

Country Status (33)

Country Link
US (2) US6930122B2 (es)
EP (1) EP1257275B1 (es)
JP (2) JP2003522145A (es)
CN (1) CN1250220C (es)
AR (1) AR028505A1 (es)
AT (1) ATE292467T1 (es)
AU (1) AU781827B2 (es)
BG (2) BG110386A (es)
BR (1) BR0108126A (es)
CA (1) CA2397262C (es)
CZ (1) CZ296685B6 (es)
DE (1) DE60109903T2 (es)
DK (1) DK1257275T3 (es)
EE (1) EE04836B1 (es)
ES (1) ES2240416T3 (es)
FR (1) FR2804604B1 (es)
HK (1) HK1051140A1 (es)
HU (1) HU225328B1 (es)
IL (1) IL150710A0 (es)
IS (1) IS6450A (es)
MX (1) MXPA02007766A (es)
NO (1) NO324521B1 (es)
NZ (1) NZ519924A (es)
PL (1) PL201685B1 (es)
PT (1) PT1257275E (es)
RS (1) RS50404B (es)
RU (1) RU2257207C2 (es)
SI (1) SI1257275T1 (es)
SK (1) SK284952B6 (es)
TW (1) TWI243677B (es)
UA (1) UA72783C2 (es)
WO (1) WO2001058450A2 (es)
ZA (1) ZA200205317B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
DE60229954D1 (de) 2001-08-13 2009-01-02 Finisar Corp Verfahren zur durchführung des einbrennens elektronischer vorrichtungen auf nicht vereinzelte halbleiterscheiben
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
US7405221B2 (en) 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2510785C (en) 2002-12-19 2013-04-09 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2007510647A (ja) * 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
CN101014605A (zh) 2004-07-12 2007-08-08 卡地拉健康护理有限公司 用作大麻素受体调节物的三环吡唑衍生物
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
EP2083799A1 (en) * 2006-10-20 2009-08-05 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
ES2240416T3 (es) 2005-10-16
SK11292002A3 (sk) 2003-02-04
CZ296685B6 (cs) 2006-05-17
WO2001058450A3 (fr) 2002-04-25
ATE292467T1 (de) 2005-04-15
ZA200205317B (en) 2003-09-04
EP1257275A2 (fr) 2002-11-20
FR2804604A1 (fr) 2001-08-10
BR0108126A (pt) 2003-01-28
JP2003522145A (ja) 2003-07-22
NZ519924A (en) 2005-01-28
IL150710A0 (en) 2003-02-12
EE04836B1 (et) 2007-06-15
HUP0300237A2 (hu) 2003-07-28
SK284952B6 (sk) 2006-03-02
US20030087933A1 (en) 2003-05-08
CA2397262A1 (en) 2001-08-16
EP1257275B1 (fr) 2005-04-06
CN1406128A (zh) 2003-03-26
US6930122B2 (en) 2005-08-16
MXPA02007766A (es) 2002-10-11
JP2010018622A (ja) 2010-01-28
AU3562001A (en) 2001-08-20
AU781827B2 (en) 2005-06-16
PL201685B1 (pl) 2009-04-30
RU2257207C2 (ru) 2005-07-27
UA72783C2 (en) 2005-04-15
NO324521B1 (no) 2007-11-12
CA2397262C (en) 2007-09-11
BG106946A (bg) 2003-05-30
DE60109903T2 (de) 2006-02-09
CZ20022698A3 (cs) 2002-11-13
FR2804604B1 (fr) 2005-05-27
HK1051140A1 (en) 2003-07-25
DE60109903D1 (de) 2005-05-12
EE200200439A (et) 2003-12-15
CN1250220C (zh) 2006-04-12
NO20023765L (no) 2002-10-09
RU2002118309A (ru) 2004-02-20
HUP0300237A3 (en) 2003-09-29
YU59002A (sh) 2005-07-19
PL358221A1 (en) 2004-08-09
IS6450A (is) 2002-06-28
BG65856B1 (bg) 2010-03-31
TWI243677B (en) 2005-11-21
RS50404B (sr) 2009-12-31
HU225328B1 (en) 2006-09-28
NO20023765D0 (no) 2002-08-08
US20050187253A1 (en) 2005-08-25
WO2001058450A2 (fr) 2001-08-16
DK1257275T3 (da) 2005-08-08
BG110386A (en) 2009-09-30
PT1257275E (pt) 2005-07-29
SI1257275T1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
AR028505A1 (es) Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco
CL2004000860A1 (es) Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
CL2004000861A1 (es) Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp
HN2004000109A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
SV2003001102A (es) Ligandos del receptor de 5-ht y sus usos ref. pc11892
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
DE60106954D1 (de) Resorcin-derivate
UY28348A1 (es) Compuestos novedosos
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
SV2009003403A (es) Extrudidos con enmascaramiento del sabor mejorado
AR048087A1 (es) Uso de antagonistas del receptor cb1 para la elaboracion de una composicion util para el tratamiento de enfermedades hepaticas
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
BR0011174A (pt) Composições, compostos, compostos isolados e métodos para controlar pestes
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
BR0101437A (pt) Método para preparar um ciclopropeno
ECSP055992A (es) Composición espermicidal y/o antifungica y metodos de uso de la misma

Legal Events

Date Code Title Description
FB Suspension of granting procedure